| |
Free HIV Testing
Building Bridges, Inc. uses three (3) type of andibody test for HIV testing: Two (2) types of Oral devices: OraQuick Advance, and OraSure. One (1) type or blood device: Clearview.
1. The OraSure Oral Specimen Collection Device is a generic device which was developed and FDA approved for the purpose of collecting, preserving, and transporting oral fluid specimens.
The OraSure device uses a simple, two minute collection procedure which can be performed by any trained personnel. It completely eliminates the risk associated with handling needles and blood.
2. The OraQuick rapid test platform for fingerstick whole blood, has been appoved by the FDA for testing for HIV-1 antibodies. The company is working on extending the intended use of the device to other samples like oral fluid and serum/plasma for the presence of various antigens. After collection, the pad is inserted into a vial containing a pre-mixed amount of developer solution and allowed to develop.
When whole blood, serum or plasma is to be tested, a loop collection device is used to collect the sample. The collection pad is then inserted into the solution. Hence the specimen and solution flows through the testing device where the results are observable in approximately 20 minutes.
The Company believes that OraQuick provides a platform technology that can be utilized for the detection of a variety of infectious diseases, such as HIV, viral hepatitis, syphilis, and other diseases.
Clearview HIV 1/2 STAT-PAK is a rapid qualitative screening test for the detection of antibodies to HIV-1 and HIV-2 in human whole blood, serum and plasma. Clearview is a simple two step procedure for whole blood.
Clearly different
Clearview's innovative technology provides highly accurate detection of HIV-1 and HIV-2.
-
Fast: two easy steps with a reactive result in as little as 15 minutes
-
Easy: CLIA-waived, easy-to-use test requires no training
-
Reliable: built-in control ensures accuracy
-
Flexible: use with multiple specimen types - whole blood (fingerstick or venipuncture), serum or plasma. Clearly
Clearview HIV 1/2 STAT-PAK provides answers for immediate and necessary treatment.
- Supports early screening and diagnosis of human immunodeficiency virus
- Detection and proper treatment may prevent transmission to an unborn child, as well as to sexual partners
- Early diagnosis and treatment can lead to a prolonged survival rate
- 24 month shelf life provides flexibility to the laboratory
- Reliable results - 99.7% sensitive, 99.9% specific
About HIV
Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) remain leading causes of illness and death in the United States. However, at the end of 2003, of the approximately 1.0--1.2 million persons estimated to be living with HIV in the United States, an estimated one quarter (252,000--312,000 persons) were unaware of their infection and therefore unable to benefit from clinical care to reduce morbidity and mortality. A number of these persons are likely to have transmitted HIV unknowingly. 1
Treatment has improved survival rates dramatically, especially since the introduction of highly active antiretroviral therapy (HAART) in 1995. However, progress in effecting earlier diagnosis has been insufficient. The good news is that the new CDC guidelines have removed much of the barriers to screening and now encourages testing all persons 13-64 years of age in the United States.
In September 2006, the CDC announced revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. The new guidelines highlight:
- Screening for all patients aged 13-64 years regardless of risk
- Patients are notified that testing will be performed unless they decline (opt-out screening)
- Testing process is streamlined to lower the barriers of pre-test counseling and documented written consent
- High risk populations such as IV drug users and their sex partners and men who have sex with men should be tested annually
This represents a substantial change from earlier recommendations:
- Offer HIV testing routinely to all patients only in health-care settings with high HIV prevalence
- Conduct targeted screening on the basis of risk behaviors for patients in low-prevalence settings
- Require informed, written consent prior to testing
- Pre-test counseling
Clearview Product Overview
The Clearview HIV 1/2 STAT-PAK is a rapid in vitro qualitative immunoassay for the detection of antibodies to HIV1 and HIV 2 in human whole blood, serum and plasma.
With its simple, two-step procedure, Clearview HIV 1/2 STAT-PAK is quick and easy to use, delivering clear, dependable results in just 15 minutes. Plus, Clearview HIV 1/2 STAT-PAK is waived for whole blood and requires a very small sample amount, making it easier to run and manage in a busy laboratory environment.
Clearview HIV-1/2 STAT-PAK will help healthcare workers diagnose individual infection, prevent mother-to-child transmission, and monitor HIV prevalence.
Clearview HIV 1/2 STAT-PAK is a rapid qualitative screening test for the detection of antibodies to HIV-1 and HIV-2 in human whole blood, serum and plasma.
|
|
